SUMMARY Cyclosporin A (CyA), a new immunosuppressive drug, is used for the prevention of organ graft
rejection in man. The main side effect of CyA is nephrotoxicity which is usually reversible when the drug is stopped. Nephrotoxicity may be avoided in patients by careful monitoring of serum CyA concentration by radioimmunoassay, in addition to the routine biochemical tests of renal function. There is a good correlation between trough (12 hour) serum concentrations of CyA and plasma creatinine.
Cyclosporin A was stable in serum at room temperature for up to seven days and on storage at -20°C for up to five months. Delayed separation of blood stored at room temperature led to increased serum CyA concentrations while blood stored at 4°C before separation was much more stable.
Blood samples should be separated as quickly as possible to avoid the release of CyA from the cellular fraction into the serum. Haemolysed samples should be avoided. CyA is sufficiently stable at room temperature for serum samples to be sent in the first class post to a control laboratory for CyA assay. after patients are discharged from the transplant centre. Control and patient serum samples should be stored for a maximum of five months at -20°C prior to assay for CyA.
Cyclosporin A (CyA) is a fungal metabolite with a cyclic structure consisting of 11 amino acids and has a molecular weight of 1202.6 daltons.' The powerful immunosuppressive effect of CyA has been used clinically to prevent rejection of organ grafts in man2 and to prevent graft versus host disease in allogeneic bone marrow transplantation.3
Mild nephrotoxicity occurs in most patients treated with CyA and cases of established renal failure have been reported.
We have found careful monitorino of serum CyA concentration using radioimmnunoassay (RIA) useful in the management of bone marrow transplant patients receiving the drug. There is a good correlation between predose (trough) CyA serum concentration and nephrotoxicity which is most apparent when other nephrotoxic drugs are given concurrently with CyA. 4 Bone marrow transplantation is carried out in specialised centres but after discharge from hospital. patients may be followed up at other hospitals some distance from the transplant centre. It is important that pharmacological monitoring should continue at this stage. The most effective way to continue monitoring patients is for blood samples to be sent by post to the transplant centre where the RIA for CyA is routinely performed.
The purpose of this study was to investigate the stability of CyA in serum on storage under different conditions and to define the best method of handling Accepted for publication 9 August 1982 blood samples which are sent to transplant centres for assay. In addition we present some data on the long-term stability of CyA in serum samples stored at -20°C.
Material and methods
Patients were given CyA orally every 12 h. Venous blood was collected from patients just prior to the next dose to measure 12 h (trough) concentrations of CyA in the serum. Blood samples were separated at 1100 g for 10 min at 40C.
MEASUREMEINT oFr C A Cyclosporin A was measured by RIA using tritiated CyA (H-_3CyA) as a tracer and an antibody supplied in kit form by Sandoz Ltd, Basle. Determinations were performed in triplicate using 20 pl serum samples diluted 1/50 with 0 05 M Tris buffer, pH 8 5.5
The interassay variation was ±5%1c and the assay was sensitive in the range 60-4000 ng'ml. Concentration of CyA in the unknown samples was calculated from a standard curve. The standard error and 95%/s confidence limits (±2SEM) were calculated for each result. Table I shows an increase of serum CyA measured in blood samples stored at room temperature for 24 h before separation. This effect was greatest in a haemolysed sample (PRO) with an increase of 42c4 over the control.
However, a repeat sample from the samile patient (PR,) was not haemolysed and only a small increase in CyA (2%k) was seen. CyA is more stable in serum when whole blood samples are stored at 4°C before separation ( thawed before standing at room temperature (Tables 3 and   4 ). Repeated freezing and thawing! (Table 4 ) of serum sample did not affect the stability of CyA as measured by RIA. CyA was stable in a previously frozen serum sample for up to seven days at room temperature (Table 5 ). marked when the unseparated blood is left at room temperature than when it is stored at 4°C. The greatest increase in CyA concentration was noticed in a haemolysed sample (Table 1) . It has been shown that 58% of whole blood CyA is bound to the red cell membrane with 33% in the plasma fraction (T Beveridge, personal communication 1981). This suggests that the rise in serum CyA seen after delayed separation of blood samples is due to release of CyA from the cellular fraction. Ideally blood samples to monitor serum CyA should be carefully taken to avoid haemolysis just before the drug is given (12 hours post dose). Samples should be separated within one hour of collection. If separation is delayed the clotted blood should be kept at 4°C. Cyclosporin A appears to be stable on short term storage of serum samples which have been separated immediately (Tables 3-5 ). Repeated freeze-thawing and storage of separated serum samples for up to one week at room temperature does not affect the measurement of CyA by RIA. Separated serum samples can therefore be sent through the post without freezing, provided reason- 
